Opinion statement
There is considerable clinical evidence that hyperglycemia at the onset of acute ischemic stroke may negatively impact not only acute morbidity but also brain recovery. Establishing hyperglycemia treatment protocols is challenging, given the variation among patients and acute stroke care settings. Relatively few randomized trials have examined glycemic control protocols in this population, and there is not yet any clear evidence that “correcting” hyperglycemia in patients with acute stroke leads to better functional outcomes. Intensification of glucose regimens, using lower glucose targets, leads to more hypoglycemic events, but the immediate and long-term impact of these events on the acutely ischemic brain is unknown. It is reasonable to treat patients with acute ischemic stroke according to the American Diabetes Association inpatient glycemic control guidelines, initiating therapy to achieve glucose targets of 140 to 180 mg/dL if fasting glucose is greater than 140 mg/dL or random glucose is consistently higher than 180 mg/dL. Lower glucose targets (<140 mg/dL) may be appropriate for patients with well-controlled diabetes and those with stress hyperglycemia who were not known to be diabetic before admission, but glucose levels less than 80 mg/dL should be avoided. Patients who present with extreme or persistent hyperglycemia, are critically ill, or who are treated with thrombolytic therapy should be started on an established and standardized intravenous insulin protocol to improve blood glucose control for at least the first 24 to 48 h of hospitalization. They should then be transitioned to a subcutaneous insulin regimen that includes basal long-acting insulin along with correction rapid-acting insulin for glucose that is out of range. Prandial (meal) insulin should be added for patients who are eating; this would preferably be a rapid-acting insulin analogue that can be administered immediately before or after the meal. Caution and close glucose monitoring are necessary, especially for patients prone to hypoglycemia, such as those with type 1 diabetes mellitus or hepatic or renal impairment, or those on complicated feeding regimens.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance ••Of major importance
Center for Disease Control: FastStats, Death and Mortality (2007). Available at http://www.cdc.gov/nchs/fastats/deaths.htm. Accessed January 2011.
Jamrozik K, Broadhurst RJ, Anderson CS, et al. The role of lifestyle factors in the etiology of stroke. A population-based case-control study in Perth, Western Australia. Stroke. 1994;25:51–9.
Baird TA, Parsons MW, Barber PA, et al. The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. J Clin Neurosci. 2002;9:618–26.
Lindsberg PJ, Roine RO. Hyperglycemia in acute stroke. Stroke. 2004;35:363–4.
Bruno A, Biller J, Adams HP, et al. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology. 1999;52:280–4.
Parsons MW, Barber PA, Desmond PM, et al. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol. 2002;52:20–8.
Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. 2001;32:2426–32.
Scott JF, Robinson GM, French JM, et al. Prevalence of admission hyperglycaemia across clinical subtypes of acute stroke. Lancet. 1999;353:376–7.
Egi M, Bellomo R, Stachowski E, et al.: Blood glucose concentration and outcome of critical illness: the impact of diabetes. Crit Care Med 2008, 36: 2249–55.
Kavanagh BP and McCowen KC: Clinical practice. Glycemic control in the ICU. N Engl J Med 2010, 363: 2540–6.
Marik PE, Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med. 2004;30:748–56.
Monnier L, Colette C, Mas E, et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia. 2010;53:562–71.
Bruno A, Liebeskind D, Qing H, et al.: Diabetes mellitus, acute hyperglycemia, and ischemic stroke. Curr Treat Options Neurol 2010, 12: 492–503.
McCormick M, Hadley D, McLean JR, et al.: Randomized, controlled trial of insulin for acute poststroke hyperglycemia. Ann Neurol 2010, 67:570–8.
Baird TA, Parsons MW, Phanh T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke. 2003;34:2208–14.
Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA stroke trial. Neurology. 2002;59:669–74.
Ahmed N, Davalos A, Eriksson N, et al.: Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol 2010, 67: 1123–30.
Meurer WJ, Scott PA, Caveney AF, et al. Lack of association between hyperglycaemia at arrival and clinical outcomes in acute stroke patients treated with tissue plasminogen activator. Int J Stroke. 2010;5:163–6.
Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) study group. BMJ. 1997;314:1512–5.
Latham R, Lancaster AD, Covington JF, et al. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Contr Hosp Epidemiol. 2001;22:607–12.
Schmeltz LR, DeSantis AJ, Thiyagarajan V, et al. Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. Diabetes Care. 2007;30:823–8.
NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al.: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360:1283–97.
Moghissi ES, Korytkowski MT, DiNardo M, et al.: American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocrine Practice 2009, 15: 353–69.
Gray CS, Hildreth AJ, Sandercock PA, et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol. 2007;6:397–406.
Bruno A, Kent TA, Coull BM, et al.: Treatment of Hyperglycemia in Ischemic Stroke (THIS): a randomized pilot trial. Stroke 2008, 39:384–9.
Johnston KC, Hall CE, Kissela BM, et al.: Glucose Regulation in Acute Stroke Patients (GRASP) trial: a randomized pilot trial. Stroke 2009, 40:3804–9.
Adams HP, Del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. [Erratum appears in Circulation. 2007 Oct 30;116(18):e515]. Circulation. 2007;115:e478–534.
Griesdale DEG, et al.: Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ Canadian Medical Association Journal, 2009. 180: 821–7.
Arabi YM, Tamim HM, Rishu AH. Hypoglycemia with intensive insulin therapy in critically ill patients: predisposing factors and association with mortality. Critical Care Medicine. 2009;37:2536–44.
Van den Berghe G, Schetz M, Vlasselaers D, et al. Clinical review: intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target? J Clin Endocrinol Metab. 2009;94:3163–70.
Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32:1335–43.
Nazer LH, Chow SL, Moghissi ES. Insulin infusion protocols for critically ill patients: a highlight of differences and similarities. Endocr Pract. 2007;13:137–46.
Krikorian A, Ismail-Beigi F, and Moghissi ES: Comparisons of different insulin infusion protocols: a review of recent literature. Curr Opin Clin Nutr Metab Care. 2010, 13:198–204.
Walters MR, Weir CJ, Lees KR. A randomized, controlled pilot study to investigate the potential benefit of intervention with insulin in hyperglycaemic acute ischaemic stroke patients. Cerebrovasc Dis. 2006;22:116–22.
Kreisel SH, Berschin UM, Hammes HP, et al. Pragmatic management of hyperglycaemia in acute ischaemic stroke: safety and feasibility of intensive intravenous insulin treatment. Cerebrovasc Dis. 2009;27:167–75.
Disclosure
Conflicts of Interest: L. Baker: none; A. Bruno: none; R. Juneja: on Speakers Bureau for Eli Lilly, Sanofi-Aventis, Merck, Amylin Pharmaceuticals, Boehringer-Ingelheim; consultant for Eli Lilly and Sanofi-Aventis; royalties from commercial sales of the Clarian Glucose Stabilizer Insulin Dosing Tool software (Diabetes Innovations, LLC); stock ownership in Amylin Pharmaceuticals.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Baker, L., Juneja, R. & Bruno, A. Management of Hyperglycemia in Acute Ischemic Stroke. Curr Treat Options Neurol 13, 616–628 (2011). https://doi.org/10.1007/s11940-011-0143-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11940-011-0143-8